Inmarsat Extends Partnership With CSG To Empower Cloud-Based Monetisation of Its Mobile Broadband Services
4.11.2020 11:00:00 EET | Business Wire | Press release
CSG ® (NASDAQ: CSGS) today announced that it has expanded its relationship with Inmarsat, a leader in global, mobile satellite communications. As part of this multi-year agreement, Inmarsat is moving its billing and revenue management operations to a consolidated, cloud-based managed services model developed by CSG, replacing existing third-party and bespoke legacy solutions.
“For nearly 20 years, CSG has worked with Inmarsat to get the most out of our billing and revenue management operations, enabling the introduction of new products and services while increasing efficiencies across our business,” said David Thornhill, senior vice president, Group IT Inmarsat. “By moving to a cloud-based managed services model, CSG will foster a more agile, cost-effective approach to how we operate our retail and wholesale business while creating a sustainable model for future success."
By utilising the CSG managed services solution, the British operator will benefit from increased process agility, go-to-market flexibility, and access to precision insights across all operations, while streamlining billing operations and lowering operating expenditures that were associated with prior third-party solutions.
The new agreement deploys the latest versions of CSG Singleview, CSG Interconnect, and CSG Intermediate, already in use by Inmarsat, helping them maximise profitability, reduce operational costs, and meet customer demands in real-time. Additional capabilities facilitate proactive identification and resolution of customer issues. In its entirety, the new cloud-based solution provides a future-proof architecture that takes advantage of best practices in billing and revenue management and enhances the customer experience.
“As Inmarsat looks to advance satellite, airborne, and maritime connectivity across Europe and beyond, we look forward to continuing our long-standing partnership, supporting the optimisation of their billing and revenue management operations, while helping them minimise risk and lower operating costs,” said James Kirby, head of CSG's EMEA business. “We are thrilled to expand our relationship with Inmarsat to help grow the business across their entire portfolio.”
CSG is recognised as a leader in the Gartner Magic Quadrant for its Revenue and Customer Management solutions, supporting hundreds of millions of end-users worldwide. The company provides monetisation, settlement and customer care solutions that help clients launch innovative digital services while transitioning off legacy systems at their own pace. CSG’s Wholesale Business Management Solution has won multiple awards for its cloud functionality and innovation and received the Global Stratecast CSP Monetisation Interconnect & Settlement Market Leadership Award from Frost & Sullivan in recent years.
About CSG
For more than 35 years, CSG has simplified the complexity of business, delivering innovative customer engagement solutions that help companies acquire, monetise, engage, and retain customers. Operating across more than 120 countries worldwide, CSG manages billions of critical customer interactions annually, and its award-winning suite of software and services allow companies across dozens of industries to tackle their biggest business challenges and thrive in an ever-changing marketplace.
CSG is the trusted partner for driving digital innovation for hundreds of leading global brands, including AT&T, Charter Communications, Comcast, DISH, Eastlink, Formula One, MTN and Telstra.
To learn more, visit our website at csgi.com and connect with us on LinkedIn and Twitter.
Copyright © 2020 CSG Systems International, Inc. and/or its affiliates (“CSG”). All rights reserved. CSG® is a registered trademark of CSG Systems International, Inc. All third-party trademarks, service marks, and/or product names which are referenced in this document are the property of their respective owners, and all rights therein are reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005049/en/
Contact information
Brad Jones
Global / North America / Asia-Pacific Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com
Kristine Østergaard
CSG
Europe / Middle East / Africa Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com
Liz Bauer
Investor Relations
CSG
+1 (303) 804-4065
liz.bauer@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom